Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NIS793 +/- spartalizumab in advanced malignancies
NCT02947165Phase 1Completed
- Sponsor
- Novartis
- Start
- Apr 2017
- Primary completion
- Jun 2021
- Modality
- Monoclonal Antibodies
- Countries
- 9
01
Overview
Phase 1, open-label trial of nisevokitug in solid tumor (advanced stage), non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC) and 4 more (2 arms), sponsored by Novartis. Primary endpoints: Incidence of Dose Limiting Toxicities and Incidence of Adverse Events. Started Apr 2017; status: completed.
02
Drugs
nisevokitug
03
Conditions
solid tumor (advanced stage)non-small cell lung cancer (NSCLC)triple-negative breast cancer (TNBC)hepatocellular carcinoma (HCC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT02947165.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02947165.